Financial Ratios

BLISS GVS PHARMA LTD.

NSE : BLISSGVSBSE : 506197ISIN CODE : INE416D01022Industry : Pharmaceuticals & DrugsHouse : Private
BSE112.65-1.5 (-1.31 %)
PREV CLOSE ( ) 114.15
OPEN PRICE ( ) 115.70
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 39688
TODAY'S LOW / HIGH ( )112.00 116.35
52 WK LOW / HIGH ( )69.15 148.95
NSE112.85-1.2 (-1.05 %)
PREV CLOSE( ) 114.05
OPEN PRICE ( ) 115.80
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 112.85 (5478)
VOLUME 367160
TODAY'S LOW / HIGH( ) 111.55 116.70
52 WK LOW / HIGH ( )69.2 149.6
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)8.218.946.548.957.22
   CEPS(Rs)9.6610.277.889.817.77
   DPS(Rs)0.500.500.500.501.00
   Book NAV/Share(Rs)89.1181.1672.3166.2158.49
   Tax Rate(%)26.1226.6925.9824.1437.98
Margin Ratios
   Core EBITDA Margin(%)15.0717.1619.6522.6621.82
   EBIT Margin(%)21.0220.5420.8629.0428.87
   Pre Tax Margin(%)19.3419.8619.5927.5428.13
   PAT Margin (%)14.2914.5614.5020.8917.45
   Cash Profit Margin (%)16.8216.7417.4622.8918.80
Performance Ratios
   ROA(%)7.709.157.5011.6110.41
   ROE(%)9.6611.689.4514.3613.00
   ROCE(%)12.8914.6812.0217.7518.80
   Asset Turnover(x)0.540.630.520.560.60
   Sales/Fixed Asset(x)1.832.652.252.994.82
   Working Capital/Sales(x)1.041.060.880.850.88
Efficiency Ratios
   Fixed Capital/Sales(x)0.550.380.440.330.21
   Receivable days246.41217.24295.44308.46267.22
   Inventory Days50.1049.8456.5547.6640.49
   Payable days92.7880.1188.4266.9353.67
Valuation Parameters
   PER(x)8.688.6115.0811.2624.94
   PCE(x)7.377.4912.5310.2823.15
   Price/Book(x)0.800.951.371.523.08
   Yield(%)0.700.650.510.500.56
   EV/Net Sales(x)1.231.152.122.364.30
   EV/Core EBITDA(x)5.215.178.917.5914.23
   EV/EBIT(x)5.845.6110.178.1114.89
   EV/CE(x)0.640.681.041.222.49
   M Cap / Sales1.241.252.192.354.35
Growth Ratio
   Net Sales Growth(%)-5.9736.705.333.6043.20
   Core EBITDA Growth(%)-0.6427.92-19.176.4029.61
   EBIT Growth(%)-3.8134.62-24.334.2031.32
   PAT Growth(%)-7.7537.28-26.9024.0530.55
   EPS Growth(%)-8.1836.58-26.9024.0530.55
Financial Stability Ratios
   Total Debt/Equity(x)0.080.100.120.130.12
   Current Ratio(x)4.764.114.635.126.28
   Quick Ratio(x)4.273.644.064.645.69
   Interest Cover(x)12.5030.2316.4019.3839.08
   Total Debt/Mcap(x)0.100.110.090.080.04

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.